File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection

TitlePrevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
Authors
Issue Date2013
PublisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm
Citation
World Journal of Gastroenterology, 2013, v. 19 n. 47, p. 8887-8894 How to Cite?
AbstractHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the majority of cases associated with persistent infection from hepatitis B virus (HBV) or hepatitis C virus (HCV). Natural history studies have identified risk factors associated with HCC development among chronic HBV and HCV infection. High-risk infected individuals can now be identified by the usage of risk predictive scores. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could also reduce the risk of HBV-related HCC. Concerning HCV infection, besides the advocation of universal precautions to reduce the rate of infection, pegylated interferon and ribavirin could also reduce the risk of HCV-related HCC among those achieving a sustained virologic response. Recently there has been mounting evidence on the role of chemopreventive agents in reducing HBV- and HCV-related HCC. The continued advances in the understanding of the molecular pathogenesis of HCC would hold promise in preventing this highly lethal cancer.
Persistent Identifierhttp://hdl.handle.net/10722/193875
ISSN
2015 Impact Factor: 2.787
2015 SCImago Journal Rankings: 1.076
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLu, Ten_US
dc.contributor.authorSeto, WKWen_US
dc.contributor.authorZhu, RXen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, RMFen_US
dc.date.accessioned2014-01-28T06:30:43Z-
dc.date.available2014-01-28T06:30:43Z-
dc.date.issued2013en_US
dc.identifier.citationWorld Journal of Gastroenterology, 2013, v. 19 n. 47, p. 8887-8894en_US
dc.identifier.issn1007-9327en_US
dc.identifier.urihttp://hdl.handle.net/10722/193875-
dc.description.abstractHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the majority of cases associated with persistent infection from hepatitis B virus (HBV) or hepatitis C virus (HCV). Natural history studies have identified risk factors associated with HCC development among chronic HBV and HCV infection. High-risk infected individuals can now be identified by the usage of risk predictive scores. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could also reduce the risk of HBV-related HCC. Concerning HCV infection, besides the advocation of universal precautions to reduce the rate of infection, pegylated interferon and ribavirin could also reduce the risk of HCV-related HCC among those achieving a sustained virologic response. Recently there has been mounting evidence on the role of chemopreventive agents in reducing HBV- and HCV-related HCC. The continued advances in the understanding of the molecular pathogenesis of HCC would hold promise in preventing this highly lethal cancer.en_US
dc.languageengen_US
dc.publisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm-
dc.relation.ispartofWorld Journal of Gastroenterologyen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titlePrevention of hepatocellular carcinoma in chronic viral hepatitis B and C infectionen_US
dc.typeArticleen_US
dc.identifier.emailSeto, WKW: wkseto2@hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hken_US
dc.identifier.authoritySeto, WKW=rp01659en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3748/wjg.v19.i47.8887en_US
dc.identifier.pmid24379612-
dc.identifier.pmcidPMC3870540-
dc.identifier.hkuros227481en_US
dc.identifier.volume19en_US
dc.identifier.issue47en_US
dc.identifier.spage8887en_US
dc.identifier.epage8894en_US
dc.identifier.isiWOS:000329129400010-
dc.publisher.placeChina-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats